Comparative efficacy of autologous platelet rich plasma and conventional dressing in the management of chronic ulcers
DOI:
https://doi.org/10.18203/2349-2902.isj20242764Keywords:
PRP, Conventional dressing, Chronic non healing ulcerAbstract
Background: Chronic ulcers pose a major global healthcare challenge. The use of platelet-rich plasma (PRP) for treating these wounds has garnered interest because of its potential healing benefits. Objective were to determine the effect of autologous PRP therapy on the percentage of surface area reduction/healing in chronic ulcers.
Methods: This randomized controlled trial was conducted at the department of general surgery of M.M. institute of medical sciences and research (M.M.I.M.S.R.) Mullana, Ambala from May 1, 2023, to April 30, 2024. Patients aged 18-80 years of either gender with chronic ulcers were enrolled. Patients were randomly allocated to the PRP group and control group. PRP group was administered autologous PRP once in two weeks for 6 weeks after debridement, while for the control group conventional saline dressings were done after debridement. Final assessment was done at 8 weeks.
Results: Of the 60 patients, the mean age was 53.90±11.23 years. There were 49 (82%) males and 11 (18%) females. At 8 weeks, the PRP group achieved 83.78% (SD=2.99) reduction in surface area of ulcers, whereas the control group had a 57.78% (SD=1.32) reduction in surface area of ulcers, with a p=0.0000 indicating a significant difference. The small sample size and 56-day follow-up period are insufficient to assess long-term treatment effects.
Conclusions: A better outcome of PRP was observed compared to conventional dressing in patients with chronic non-healing ulcers.
Metrics
References
Strohal R, Dissemond J, Jordan O’Brien J, Piaggesi A, Rimdeika R, Young T, et al. EWMA Document: Debridement: An updated overview and clarification of the principle role of debridement. J Wound Care. 2013;22:S1-49.
Sibbald RG, Elliott JA, Persaud-Jaimangal R, Goodman L, Armstrong DG, Harley C, et al. Wound Bed Preparation 2021. Adv Skin Wound Care. 2021;34(4):183-95.
Sen CK. Human wounds and its burden: An updated compendium of estimates. Adv Wound Care (New Rochelle). 2019;8(2):39-48.
Barrientos S, Brem H, Stojadinovic O, Tomic-Canic M. Clinical application of growth factors and cytokines in wound healing: Wound management: growth factors and cytokines. Wound Repair Regen. 2014;22(5):569-78.
Barrientos S, Stojadinovic O, Golinko MS, Brem H, Tomic-Canic M. Growth factors and cytokines in wound healing: Growth factors and cytokines in wound healing. Wound Repair Regen. 2008;16(5):585-601.
Phillips T. New treatments for venous leg ulcers. Clin Dermatol. 1994;12(1):35-41.
Martinez-Zapata MJ, Martí-Carvajal AJ, Solà I, Expósito JA, Bolíbar I, Rodríguez L, et al. Autologous platelet-rich plasma for treating chronic wounds. Cochrane Database Syst Rev. 2012;10(5):CD006899.
Verma R, Kumar S, Garg P, Verma YK. Platelet-rich plasma: a comparative and economical therapy for wound healing and tissue regeneration. Cell Tissue Bank. 2023;24(2):285-306.
Marx RE. Platelet-rich plasma (PRP): what is PRP and what is not PRP? Implant Dent. 2001;10(4):225-8.
Driver VR, Hanft J, Fylling CP, Beriou JM. Autologel Diabetic Foot Ulcer Study Group. A prospective, randomized, controlled trial of autologous platelet-rich plasma gel for the treatment of diabetic foot ulcers. Ostomy Wound Manage. 2006;52(6):1.
Anitua E, Aguirre JJ, Algorta J, Ayerdi E, Cabezas AI, Orive G, et al. Effectiveness of autologous preparation rich in growth factors for the treatment of chronic cutaneous ulcers. J Biomed Mater Res B Appl Biomater. 2008;84B(2):415-21.
Friese G, Herten M, Scherbaum WA. The use of autologous platelet concentrate activated by autologous thrombin (APC+) is effective and safe in the treatment of chronic diabetic foot ulcers: a randomized controlled trial. In: Fifth International Symposium on the Diabetic Foot. Noordwijkerhout, The Netherlands. 2007.
Downloads
Published
How to Cite
Issue
Section
